Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Net Income (2020 - 2023)

Candel Therapeutics' Net Income history spans 4 years, with the latest figure at -$10.6 million for Q4 2023.

  • For Q4 2023, Net Income fell 37.35% year-over-year to -$10.6 million; the TTM value through Dec 2023 reached -$38.9 million, down 12.44%, while the annual FY2024 figure was -$30.2 million, 22.39% up from the prior year.
  • Net Income for Q4 2023 was -$10.6 million at Candel Therapeutics, down from -$9.0 million in the prior quarter.
  • Across five years, Net Income topped out at -$2.6 million in Q2 2020 and bottomed at -$10.6 million in Q4 2023.
  • The 4-year median for Net Income is -$8.4 million (2021), against an average of -$7.7 million.
  • The largest annual shift saw Net Income plummeted 103.02% in 2021 before it increased 0.65% in 2022.
  • A 4-year view of Net Income shows it stood at -$6.1 million in 2020, then fell by 27.53% to -$7.8 million in 2021, then grew by 0.65% to -$7.7 million in 2022, then plummeted by 37.35% to -$10.6 million in 2023.
  • Per Business Quant, the three most recent readings for CADL's Net Income are -$10.6 million (Q4 2023), -$9.0 million (Q3 2023), and -$9.8 million (Q2 2023).